Ji-Jung Jung

Ji-Jung Jung

Auto-generated profile, based on publicly available information

Ji-Jung Jung

Department of Surgery, Seoul National University College of Medicine, Seoul, Korea

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2024 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
JJJi-Jung Jung
Ji-Jung Jung
JCJong-Ho Cheun
Jong-Ho Cheun
SKSoo-Yeon Kim
Soo-Yeon Kim
JKJiwon Koh
Jiwon Koh
JRJai Min Ryu
Jai Min Ryu
HLHan-Byoel Lee
Han-Byoel Lee
Jung JJ, et al. J Breast Cancer. 2024 Feb;27:e8. https://doi.org/10.4048/jbc.2023.0265

1 January 2023 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
JJJi-Jung Jung
Ji-Jung Jung
EKEun-Kyu Kim
Eun-Kyu Kim
EKEunyoung Kang
Eunyoung Kang
JKJee Hyun Kim
Jee Hyun Kim
SKSe Hyun Kim
Se Hyun Kim
HSHee-Chul Shin
Hee-Chul Shin
Jung JJ, et al. J Breast Cancer. 2023 Mar;26:e14. https://doi.org/10.4048/jbc.2023.26.e14

1 January 2024 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
JBJinyoung Byeon
Jinyoung Byeon
EKEunhye Kang
Eunhye Kang
JJJi-Jung Jung
Ji-Jung Jung
JCJong-Ho Cheun
Jong-Ho Cheun
KSKwan Sik Seo
Kwan Sik Seo
HMHyeong-Gon Moon
Hyeong-Gon Moon
Byeon J, et al. J Breast Cancer. 2024 Oct;27(5):323-333. https://doi.org/10.4048/jbc.2024.0180

1 January 2025 in Journal of Breast Cancer
Verified
Journal Article
Open access
PDF file
JJJi-Jung Jung
Ji-Jung Jung
HKHee Jeong Kim
Hee Jeong Kim
BCByung Joo Chae
Byung Joo Chae
EKEun-Kyu Kim
Eun-Kyu Kim
JAJee Hyun Ahn
Jee Hyun Ahn
WHWonshik Han
Wonshik Han
Jung JJ, et al. J Breast Cancer. 2025 Nov;28:e42. https://doi.org/10.4048/jbc.2025.0157

17 March 2025 in The Breast
Verified
Journal Article
Open access
MLMin Jung Lee
Min Jung Lee
JJJi-Jung Jung
Ji-Jung Jung
JCJong-Ho Cheun
Jong-Ho Cheun
EKEunhye Kang
Eunhye Kang
HKHong-Kyu Kim
Hong-Kyu Kim
WHWonshik Han
Wonshik Han
The Rx for positive node endocrine-responsive breast cancer trial highlighted that premenopausal (PRE) women who underwent chemotherapy exhibited superior survival rates compared to postmenopausal (POST) counterparts, but showed worse survival without chemotherapy. This raises the question whether application of ovarian function suppression (OFS) in PRE women aligns with their cancer biology, treatment response, and outcomes observed in POST women. Data from the Seoul National University Hospital breast cancer cohort focusing on patients with stage pT1-3, pN0-1, estrogen receptor-positive (ER+), and HER2-negative breast cancer were analyzed. Survival outcomes, including invasive disease-free survival (iDFS) and distant relapse-free survival (DRFS), were compared between PRE women receiving OFS and POST women, with chemotherapy usage as a stratification factor. Propensity score matching was performed. We analyzed 3483 patients, comprising 2901 POST and 582 PRE women with OFS. In the cohort without chemotherapy, the 10-year iDFS rates were 90.3 % and 88.3 % (hazard ratio [HR], 1.32; p = 0.16), and 10-year DRFS rates were 94.3 % and 96.1 % (HR, 0.78; p = 0.41) for POST and PRE women with OFS, respectively. Among women treated with chemotherapy, 10-year iDFS rates were 83.0 % and 79.5 % (HR, 1.21; p = 0.37), and DRFS rates were 86.7 % and 85.7 % (HR, 1.14; p = 0.58) for POST and PRE women with OFS, respectively. These results remained consistent after PSM. Oncological outcomes of PRE women receiving OFS were comparable to those of POST women with ER+ and HER2-early breast cancer, irrespective of chemotherapy administration.

12 April 2025 in European Journal of Surgical Oncology
Verified
Journal Article
Closed access
HKHyoung Won Koh
Hyoung Won Koh
JJJi-Jung Jung
Ji-Jung Jung
HKHong-Kyu Kim
Hong-Kyu Kim
HMHyeong-Gon Moon
Hyeong-Gon Moon
WHWonshik Han
Wonshik Han
HSHee-Chul Shin
Hee-Chul Shin